DALLAS, TX / ACCESSWIRE / January 18, 2022 / Aziyo Biologics, Inc. (NASDAQ:AZYO): The full report can be accessed by clicking on the following link: http://stonegateinc.
The consensus price target hints at a 123.3% upside potential for Aziyo Biologics, Inc. (AZYO). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
SILVER SPRING, Md., Dec. 27, 2021 (GLOBE NEWSWIRE) -- Aziyo Biologics, Inc. (Nasdaq: AZYO), a commercial-stage regenerative medicine company focused on creating the next generation of differentiated products and improving outcomes in patients undergoing surgery, today announced that members of management will present at the upcoming H.C. Wainwright Bioconnect Virtual Conference. A Pre-recorded presentation will be available on Monday, January 10th at 7:00 am Eastern Time. Interested parties may